Team project
Team #2 is interested in analysing the role of caspases and autophagy in the differentiation and pathophysiology of haematopoietic cells. Concurrently, we also scrutinized the mechanisms of resistance to tyrosine kinase inhibitors, nucleoside analogues and proteasome inhibitors, the leading treatments for chronic myelogenous leukaemia (CML), myelodysplastic syndromes (MDS) and multiple myeloma (MM).
Previous activities
Bcl-2 family members play an essential role in the control of apoptosis and autophagy and alterations of these processes are intimately linked with haematopoietic cell transformation. In this context, we identified an anti-apoptotic member of the Bcl2 family, Bcl-B as a new biomarker for MM, that also predicts the resistance to Vidaza® (5-azacytidine, a nucleoside analogue) at diagnosis in MDS patients. An original triazole nucleoside analogue developed in collaboration with the Chemistry Institute of Nice (CNRS7272) has now been licenced and this drug will likely enter phase I clinical trial in high-risk MDS patients. Finally, we generated transgenic mice in which the expression of the Bcl-B transgene is driven by the Eu-promoter specifically in the B cell compartment. These mice developed with age a haematopoietic malignancy that accurately replicates human MM, highlighting the key role of Bcl-B as an essential survival factor in plasmocyte differentiation and transformation.
Research Projects
Our research programme will focus on the pathophysiology and the treatment of several myeloid malignancies including MDS, acute myeloid leukaemia (AML), chronic myelomonocytic leukaemia (CMML) as well as MM. We will perform fundamental, preclinical and translational researches, studying also normal haematopoiesis for a better understanding of haematopoietic malignancy mechanisms. One of our main goals is to decipher the role of Bcl-B in myeloid malignancies and MM. We also discovered that autophagy plays a key role in the physiological differentiation of monocytes into macrophages. We showed that modulating autophagy and differentiation could represent a new therapeutic avenue in patients suffering from CMML. We identified in CMML patients a subpopulation of myeloid-derived suppressive cells (MDSCs) able to alter monocyte differentiation. In MDS, we established that Bcl-B is a new biomarker of resistance to Vidaza®. We are currently studying the role of bone marrow stromal cells in the resistance to Vidaza® and the effect of a promising family of nucleoside analogues for MDS treatment. In addition, we identified that MDS resistant cells and some AML cell lines exhibited a defect in chaperone-mediated autophagy that can be therapeutically exploited. Finally, we demonstrated that Bcl-B plays an essential role in the differentiation of plasmocytes by protecting them from cell death. In this context, our project will be developed along 3 research axis.
Axis#1: Deciphering the mechanisms of resistance to Aza in MDS/AML.
Axis#2: Dissecting the mechanisms involved in macrophage differentiation of monocytes and their alterations in CMML.
Axis#3: Investigating the role of Bcl-B in the pathophysiology of MM.
These 3 highly complementary projects will bring new and key information regarding the pathophysiology and treatment of several currently incurable haematopoietic malignancies.
Highlights
Over the 2010-2016 period, members of the Team 2 have contributed to significant advances in the field of oncohematology and resistance of hematopoietic malignancies to chemotherapies. We :
1) Developped an original transgenic mouse model which replicates accurately human MM. This mouse model represents an unvaluable tool for evaluating anti-myeloma therapies (Autophagy, 2012a, J Exp Med, 2016, Patent 2015).
2) Deciphered the signalling pathways involved in the differentiation of monocytes into macrophages, established the key role of AMPK and autophagy in this process and proposed new therapies targeting AMPK and autophagy in CMML (Autophagy 2009, Blood 2012, Autophagy, 2012b and 2015, Patent with Inserm Transfer 2015).
3) Identified the anti-apoptotic Bcl2 family member Bcl-B as a new marker of resistance to Azacytidine in MDS (Oncotarget 2012, 2014, WO-Patent 2012, Matwin 2013), validated new nucleoside analogues for the treatment of this disease (Oncotarget 2012, 2014) and licenced 2 patents to Clevexel Pharma for the diagnosis of Aza resistance in MDS/AML patients.
4) Identified defect in chaperone-mediated autophagy (due to LAMP2 deficiency) in MDS and AML (manuscript in preparation, Patent with Inserm transfert 2016).
5) Conducted a phase I/II clinical trial analyzing the impact of Acadra (Acadesine) in Aza-resistant MDS and AML patients.
6) Finally, Team 2 developped fruitful collaborations with Teams 1, 3, 4, 5, 6, 7, 11, 12 at C3M (Haematologica, 2012, Cancer Res 2010 and 2011, Plos Pathogen 2015, PNAS 2013, Leukemia 2013 and 2015).
Team Publications
-
Implication and Regulation of AMPK during Physiological and Pathological Myeloid Differentiation
Jacquel A, Luciano F, Robert G, Auberger P
Int J Mol Sci 2018 Sep;19(10) PMID : 30274374 -
Modular synthesis of new C-aryl-nucleosides and their anti-CML activity
Marzag H, Zerhouni M, Tachallait H, Demange L, Robert G, Bougrin K, Auberger P, Benhida R
Bioorg. Med. Chem. Lett. 2018 Jun;28(10):1931-1936 PMID : 29655981 -
ATP-competitive Plk1 inhibitors induce caspase 3-mediated Plk1 cleavage and activation in hematopoietic cell lines
Dufies M, Ambrosetti D, Boulakirba S, Calleja A, Savy C, Furstoss N, Zerhouni M, Parola J, Aira-Diaz L, Marchetti S, Orange F, Lacas-Gervais S, Luciano F, Jacquel A, Robert G, Pagès G, Auberger P
Oncotarget 2018 Feb;9(13):10920-10933 PMID : 29541386 -
IL-34 and CSF-1 display an equivalent macrophage differentiation ability but a different polarization potential
Boulakirba S, Pfeifer A, Mhaidly R, Obba S, Goulard M, Schmitt T, Chaintreuil P, Calleja A, Furstoss N, Orange F, Lacas-Gervais S, Boyer L, Marchetti S, Verhoeyen E, Luciano F, Robert G, Auberger P, Jacquel A
Sci Rep 2018 Jan;8(1):256 PMID : 29321503 -
Pro-inflammatory proteins S100A9 and TNFα suppress erythropoietin elaboration in myelodysplastic syndromes
Cluzeau T, McGraw KL, Irvine B, Masala E, Ades L, Basiorka AA, Maciejewski JP, Auberger P, Wei S, Fenaux P, Santini V, List A
Haematologica 2017 Oct; PMID : 28983059 -
CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas
Dufies M, Giuliano S, Viotti J, Borchiellini D, Cooley LS, Ambrosetti D, Guyot M, Ndiaye PD, Parola J, Claren A, Schiappa R, Gal J, Frangeul A, Jacquel A, Cassuto O, Grépin R, Auberger P, Bikfalvi A, Milano G, Escudier B, Rioux-Leclercq N, Porta C, Negrier S, Chamorey E, Ferrero JM, Pagès G
Br. J. Cancer 2017 Sep;117(7):947-953 PMID : 28850564 -
BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia
Vidal V, Robert G, Goursaud L, Durand L, Ginet C, Karsenti JM, Luciano F, Gastaud L, Garnier G, Braun T, Hirsch P, Raffoux E, Nloga AM, Padua RA, Dombret H, Rohrlich P, Ades L, Chomienne C, Auberger P, Fenaux P, Cluzeau T
Oncotarget 2017 Jul;8(29):47103-47109 PMID : 28514758 -
[Autophagy, a key player in leukemogenesis and a therapeutic target in hematopoietic malignancies]
Jacquel A, Luciano F, Puissant A, Robert G, Auberger P
Med Sci (Paris) 2017 Mar;33(3):226-229 PMID : 28367807 -
Synthesis and anti-cancer activities of new sulfonamides 4-substituted-triazolyl nucleosides
Alaoui S, Dufies M, Driowya M, Demange L, Bougrin K, Robert G, Auberger P, Pagès G, Benhida R
Bioorg. Med. Chem. Lett. 2017 May;27(9):1989-1992 PMID : 28325600 -
The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia
Fenouille N, Bassil CF, Ben-Sahra I, Benajiba L, Alexe G, Ramos A, Pikman Y, Conway AS, Burgess MR, Li Q, Luciano F, Auberger P, Galinsky I, DeAngelo DJ, Stone RM, Zhang Y, Perkins AS, Shannon K, Hemann MT, Puissant A, Stegmaier K
Nat. Med. 2017 Mar;23(3):301-313 PMID : 28191887 -
In Vitro and in Vivo Evaluation of Fully Substituted (5-(3-Ethoxy-3-oxopropynyl)-4-(ethoxycarbonyl)-1,2,3-triazolyl-glycosides as Original Nucleoside Analogues to Circumvent Resistance in Myeloid Malignancies
Amdouni H, Robert G, Driowya M, Furstoss N, Métier C, Dubois A, Dufies M, Zerhouni M, Orange F, Lacas-Gervais S, Bougrin K, Martin AR, Auberger P, Benhida R
J. Med. Chem. 2017 Feb;60(4):1523-1533 PMID : 28094938 -
Autophagy, a key mechanism of oncogenesis and resistance in leukemia
Auberger P, Puissant A
Blood 2017 Feb;129(5):547-552 PMID : 27956388 -
An miRNA-DNMT1 Axis Is Involved in Azacitidine Resistance and Predicts Survival in Higher-Risk Myelodysplastic Syndrome and Low Blast Count Acute Myeloid Leukemia
Solly F, Koering C, Mohamed AM, Maucort-Boulch D, Robert G, Auberger P, Flandrin-Gresta P, Adès L, Fenaux P, Kosmider O, Tavernier-Tardy E, Cornillon J, Guyotat D, Campos L, Mortreux F, Wattel E
Clin. Cancer Res. 2017 Jun;23(12):3025-3034 PMID : 27881579 -
BCL-B (BCL2L10) is overexpressed in patients suffering from multiple myeloma (MM) and drives an MM-like disease in transgenic mice
Hamouda MA, Jacquel A, Robert G, Puissant A, Richez V, Cassel R, Fenouille N, Roulland S, Gilleron J, Griessinger E, Dubois A, Bailly-Maitre B, Goncalves D, Mallavialle A, Colosetti P, Marchetti S, Amiot M, Gomez-Bougie P, Rochet N, Deckert M, Avet-Loiseau H, Hofman P, Karsenti JM, Jeandel PY, Blin-Wakkach C, Nadel B, Cluzeau T, Anderson KC, Fuzibet JG, Auberger P, Luciano F
J. Exp. Med. 2016 Aug;213(9):1705-22 PMID : 27455953 -
Differentiation inducing factor 3 mediates its anti-leukemic effect through ROS-dependent DRP1-mediated mitochondrial fission and induction of caspase-independent cell death
Dubois A, Ginet C, Furstoss N, Belaid A, Hamouda MA, El Manaa W, Cluzeau T, Marchetti S, Ricci JE, Jacquel A, Luciano F, Driowya M, Benhida R, Auberger P, Robert G
Oncotarget 2016 Mar; PMID : 27027430 -
Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia
Green AS, Maciel TT, Hospital MA, Yin C, Mazed F, Townsend EC, Pilorge S, Lambert M, Paubelle E, Jacquel A, Zylbersztejn F, Decroocq J, Poulain L, Sujobert P, Jacque N, Adam K, So JC, Kosmider O, Auberger P, Hermine O, Weinstock DM, Lacombe C, Mayeux P, Vanasse GJ, Leung AY, Moura IC, Bouscary D, Tamburini J
Sci Adv 2015 Sep;1(8):e1500221 PMID : 26601252 -
FeCl3-promoted and ultrasound-assisted synthesis of resveratrol O-derived glycoside analogs
Marzag H, Robert G, Dufies M, Bougrin K, Auberger P, Benhida R
Ultrason Sonochem 2015 Jan;22:15-21 PMID : 24961448 -
Successful re-treatment of a relapsed V600E mutated HCL patient with low-dose vemurafenib
Bailleux C, Robert G, Ginet C, Re D, Thyss A, Sudaka I, Peyrottes I, Hofman P, Auberger P, Peyrade F
Oncoscience 2015;2(1):44-9 PMID : 25815361 -
The PRKAA1/AMPKα1 pathway triggers autophagy during CSF1-induced human monocyte differentiation and is a potential target in CMML
Obba S, Hizir Z, Boyer L, Selimoglu-Buet D, Pfeifer A, Michel G, Hamouda MA, Gonçalvès D, Cerezo M, Marchetti S, Rocchi S, Droin N, Cluzeau T, Robert G, Luciano F, Robaye B, Foretz M, Viollet B, Legros L, Solary E, Auberger P, Jacquel A
Autophagy 2015 Jul;11(7):1114-29 PMID : 26029847 -
GAPDH enhances the aggressiveness and the vascularization of non-Hodgkin’s B lymphomas via NF-κB-dependent induction of HIF-1α
Chiche J, Pommier S, Beneteau M, Mondragón L, Meynet O, Zunino B, Mouchotte A, Verhoeyen E, Guyot M, Pagès G, Mounier N, Imbert V, Colosetti P, Goncalvès D, Marchetti S, Brière J, Carles M, Thieblemont C, Ricci JE
Leukemia 2015 May;29(5):1163-76 PMID : 25394713 -
NIK promotes tissue destruction independently of the alternative NF-κB pathway through TNFR1/RIP1-induced apoptosis
Boutaffala L, Bertrand MJ, Remouchamps C, Seleznik G, Reisinger F, Janas M, Bénézech C, Fernandes MT, Marchetti S, Mair F, Ganeff C, Hupalowska A, Ricci JE, Becher B, Piette J, Knolle P, Caamano J, Vandenabeele P, Heikenwalder M, Dejardin E
Cell Death Differ. 2015 Jun; PMID : 26045047 -
A new posttranslational regulation of REDD1/DDIT4 through cleavage by caspase 3 modifies its cellular function
Puissant A, Fenouille N, Robert G, Jacquel A, Bassil CF, Colosetti P, Luciano F, Auberger P
Cell Death Dis 2014;5:e1349 PMID : 25058423 -
Phenotypic and genotypic characterization of azacitidine-sensitive and resistant SKM1 myeloid cell lines
Cluzeau T, Dubois A, Jacquel A, Luciano F, Renneville A, Preudhomme C, Karsenti JM, Mounier N, Rohrlich P, Raynaud S, Mari B, Robert G, Auberger P
Oncotarget 2014 Jun;5(12):4384-91 PMID : 24962689 -
The small heat shock protein B8 (HSPB8) confers resistance to bortezomib by promoting autophagic removal of misfolded proteins in multiple myeloma cells
Hamouda MA, Belhacene N, Puissant A, Colosetti P, Robert G, Jacquel A, Mari B, Auberger P, Luciano F
Oncotarget 2014 Aug;5(15):6252-66 PMID : 25051369 -
SYK is a critical regulator of FLT3 in acute myeloid leukemia
Puissant A, Fenouille N, Alexe G, Pikman Y, Bassil CF, Mehta S, Du J, Kazi JU, Luciano F, Rönnstrand L, Kung AL, Aster JC, Galinsky I, Stone RM, DeAngelo DJ, Hemann MT, Stegmaier K
Cancer Cell 2014 Feb;25(2):226-42 PMID : 24525236 -
Glucose metabolism is inhibited by caspases upon the induction of apoptosis
Pradelli LA, Villa E, Zunino B, Marchetti S, Ricci JE
Cell Death Dis 2014;5:e1406 PMID : 25188516 -
CD271 is an imperfect marker for melanoma initiating cells
Cheli Y, Bonnazi VF, Jacquel A, Allegra M, De Donatis GM, Bahadoran P, Bertolotto C, Ballotti R
Oncotarget 2014 Jul;5(14):5272-83 PMID : 25105565 -
Monosomal karyotype improves IPSS-R stratification in MDS and AML patients treated with Azacitidine
Cluzeau T, Mounier N, Karsenti JM, Richez V, Legros L, Gastaud L, Garnier G, Re D, Montagne N, Gutnecht J, Gabriel Fuzibet J, Auberger P, Raynaud S, Cassuto JP
Am. J. Hematol. 2013 Sep;88(9):780-3 PMID : 23757315 -
Sestrin2 integrates Akt and mTOR signaling to protect cells against energetic stress-induced death
Ben-Sahra I, Dirat B, Laurent K, Puissant A, Auberger P, Budanov A, Tanti JF, Bost F
Cell Death Differ. 2013 Apr;20(4):611-9 PMID : 23238567 -
Total genomic alteration as measured by SNP-array-based molecular karyotyping is predictive of overall survival in a cohort of MDS or AML patients treated with azacitidine
Cluzeau T, Moreilhon C, Mounier N, Karsenti JM, Gastaud L, Garnier G, Re D, Montagne N, Gutnecht J, Auberger P, Fuzibet JG, Cassuto JP, Raynaud S
Blood Cancer J 2013;3:e155 PMID : 24185502 -
How recent advances in high-risk myelodysplastic syndrome physiopathology may impact future treatments
Cluzeau T, Robert G, Jacquel A, Auberger P
Curr. Pharm. Des. 2013;19(30):5362-73 PMID : 23394086 -
GAPDH binds to active Akt, leading to Bcl-xL increase and escape from caspase-independent cell death
Jacquin MA, Chiche J, Zunino B, Bénéteau M, Meynet O, Pradelli LA, Marchetti S, Cornille A, Carles M, Ricci JE
Cell Death Differ. 2013 Aug;20(8):1043-54 PMID : 23645209 -
All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to ponatinib
Cassuto O, Dufies M, Jacquel A, Robert G, Ginet C, Dubois A, Hamouda A, Puissant A, Luciano F, Karsenti JM, Legros L, Cassuto JP, Lenain P, Auberger P
Oncotarget 2012 Dec;3(12):1557-65 PMID : 23238683 -
Autophagy is required for CSF-1-induced macrophagic differentiation and acquisition of phagocytic functions
Jacquel A, Obba S, Boyer L, Dufies M, Robert G, Gounon P, Lemichez E, Luciano F, Solary E, Auberger P
Blood 2012 May;119(19):4527-31 PMID : 22452982 -
BCL2L10 is a predictive factor for resistance to azacitidine in MDS and AML patients
Cluzeau T, Robert G, Mounier N, Karsenti JM, Dufies M, Puissant A, Jacquel A, Renneville A, Preudhomme C, Cassuto JP, Raynaud S, Luciano F, Auberger P
Oncotarget 2012 Apr;3(4):490-501 PMID : 22577154 -
Imatinib triggers mesenchymal-like conversion of CML cells associated with increased aggressiveness
Puissant A, Dufies M, Fenouille N, Ben Sahra I, Jacquel A, Robert G, Cluzeau T, Deckert M, Tichet M, Chéli Y, Cassuto JP, Raynaud S, Legros L, Pasquet JM, Mahon FX, Luciano F, Auberger P
J Mol Cell Biol 2012 Aug;4(4):207-20 PMID : 22467682 -
Proper macrophagic differentiation requires both autophagy and caspase activation
Jacquel A, Obba S, Solary E, Auberger P
Autophagy 2012 Jul;8(7):1141-3 PMID : 22751215 -
The caspase 6 derived N-terminal fragment of DJ-1 promotes apoptosis via increased ROS production
Robert G, Puissant A, Dufies M, Marchetti S, Jacquel A, Cluzeau T, Colosetti P, Belhacene N, Kahle P, Da Costa CA, Luciano F, Checler F, Auberger P
Cell Death Differ. 2012 Nov;19(11):1769-78 PMID : 22555455 -
Metformin inhibits melanoma development through autophagy and apoptosis mechanisms
Tomic T, Botton T, Cerezo M, Robert G, Luciano F, Puissant A, Gounon P, Allegra M, Bertolotto C, Bereder JM, Tartare-Deckert S, Bahadoran P, Auberger P, Ballotti R, Rocchi S
Cell Death Dis 2011;2:e199 PMID : 21881601 -
Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1
Ben Sahra I, Regazzetti C, Robert G, Laurent K, Le Marchand-Brustel Y, Auberger P, Tanti JF, Giorgetti-Peraldi S, Bost F
Cancer Res. 2011 Jul;71(13):4366-72 PMID : 21540236 -
Azacitidine-resistant SKM1 myeloid cells are defective for AZA-induced mitochondrial apoptosis and autophagy
Cluzeau T, Robert G, Puissant A, Jean-Michel K, Cassuto JP, Raynaud S, Auberger P
Cell Cycle 2011 Jul;10(14):2339-43 PMID : 21654192 -
Mechanism of action of the multikinase inhibitor Foretinib
Dufies M, Jacquel A, Robert G, Cluzeau T, Puissant A, Fenouille N, Legros L, Raynaud S, Cassuto JP, Luciano F, Auberger P
Cell Cycle 2011 Dec;10(23):4138-48 PMID : 22101270 -
Mechanisms of AXL overexpression and function in Imatinib-resistant chronic myeloid leukemia cells
Dufies M, Jacquel A, Belhacene N, Robert G, Cluzeau T, Luciano F, Cassuto JP, Raynaud S, Auberger P
Oncotarget 2011 Nov;2(11):874-85 PMID : 22141136 -
The p53/p21Cip1/ Waf1 pathway mediates the effects of SPARC on melanoma cell cycle progression
Fenouille N, Robert G, Tichet M, Puissant A, Dufies M, Rocchi S, Ortonne JP, Deckert M, Ballotti R, Tartare-Deckert S
Pigment Cell Melanoma Res 2011 Feb;24(1):219-32 PMID : 20955243 -
AMPK- and p62/SQSTM1-dependent autophagy mediate resveratrol-induced cell death in chronic myelogenous leukemia
Puissant A, Auberger P
Autophagy 2010 Jul;6(5):655-7 PMID : 20458181 -
Glycolysis inhibition sensitizes tumor cells to death receptors-induced apoptosis by AMP kinase activation leading to Mcl-1 block in translation
Pradelli LA, Bénéteau M, Chauvin C, Jacquin MA, Marchetti S, Muñoz-Pinedo C, Auberger P, Pende M, Ricci JE
Oncogene 2010 Mar;29(11):1641-52 PMID : 19966861 -
Targeting autophagy to fight hematopoietic malignancies
Puissant A, Robert G, Auberger P
Cell Cycle 2010 Sep;9(17):3470-8 PMID : 20703092 -
Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells
Ben Sahra I, Laurent K, Giuliano S, Larbret F, Ponzio G, Gounon P, Le Marchand-Brustel Y, Giorgetti-Peraldi S, Cormont M, Bertolotto C, Deckert M, Auberger P, Tanti JF, Bost F
Cancer Res. 2010 Mar;70(6):2465-75 PMID : 20215500 -
Transcriptome dysregulation by anthrax lethal toxin plays a key role in induction of human endothelial cell cytotoxicity
Rolando M, Stefani C, Flatau G, Auberger P, Mettouchi A, Mhlanga M, Rapp U, Galmiche A, Lemichez E
Cell. Microbiol. 2010 Jul;12(7):891-905 PMID : 20088950 -
Autophagy is an important event for megakaryocytic differentiation of the chronic myelogenous leukemia K562 cell line
Colosetti P, Puissant A, Robert G, Luciano F, Jacquel A, Gounon P, Cassuto JP, Auberger P
Autophagy 2009 Nov;5(8):1092-8 PMID : 19786835 -
Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitors
Grosso S, Puissant A, Dufies M, Colosetti P, Jacquel A, Lebrigand K, Barbry P, Deckert M, Cassuto JP, Mari B, Auberger P
Mol. Cancer Ther. 2009 Jul;8(7):1924-33 PMID : 19567819 -
Inhibition of imatinib-mediated apoptosis by the caspase-cleaved form of the tyrosine kinase Lyn in chronic myelogenous leukemia cells
Gamas P, Marchetti S, Puissant A, Grosso S, Jacquel A, Colosetti P, Pasquet JM, Mahon FX, Cassuto JP, Auberger P
Leukemia 2009 Aug;23(8):1500-6 PMID : 19340007 -
Injection of Staphylococcus aureus EDIN by the Bacillus anthracis protective antigen machinery induces vascular permeability
Rolando M, Munro P, Stefani C, Auberger P, Flatau G, Lemichez E
Infect. Immun. 2009 Sep;77(9):3596-601 PMID : 19546197 -
Modulation of caspase-independent cell death leads to resensitization of imatinib mesylate-resistant cells
Lavallard VJ, Pradelli LA, Paul A, Bénéteau M, Jacquel A, Auberger P, Ricci JE
Cancer Res. 2009 Apr;69(7):3013-20 PMID : 19318579 -
The caspase-cleaved form of LYN mediates a psoriasis-like inflammatory syndrome in mice
Marchetti S, Gamas P, Belhacène N, Grosso S, Pradelli LA, Colosetti P, Johansen C, Iversen L, Deckert M, Luciano F, Hofman P, Ortonne N, Khemis A, Mari B, Ortonne JP, Ricci JE, Auberger P
EMBO J. 2009 Aug;28(16):2449-60 PMID : 19590497 -
Spleen tyrosine kinase functions as a tumor suppressor in melanoma cells by inducing senescence-like growth arrest
Bailet O, Fenouille N, Abbe P, Robert G, Rocchi S, Gonthier N, Denoyelle C, Ticchioni M, Ortonne JP, Ballotti R, Deckert M, Tartare-Deckert S
Cancer Res. 2009 Apr;69(7):2748-56 PMID : 19293188